NewLink Genetics Corporation (NLNK) belongs to the “Healthcare” sector with an industry focus on “Biotechnology”, with Mr. Charles J. Link Jr., M.D. as Co-Founder, Chairman, Chief Exec. Officer & Chief Scientific Officer.
The company has been one of the biggest innovators in “Biotechnology” employing approximately 122 full time employees.
- The stock added in the prior trading session by 74.58%, closing at the stock price of $13.6.
- Currently, the market capitalization of NewLink Genetics Corporation (NLNK) is 400.13 Million.
- NLNK has a 1-year high price of $ 25.17 and 1-year low price of $5.90.
- The number of shares currently held by investors is 29.42 Million.
- The number of shares traded in the last trading session was 28.77 Million.
The company reported an impressive total revenue of 35.77 Million in the last fiscal year.
If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, NLNK earned gross profit of 0, in 2015 0 gross profit, while in 2016 NewLink Genetics Corporation (NLNK) produced 0 profit.
Currently the shares of NewLink Genetics Corporation (NLNK) has a trading volume of 28.77 Million shares, with an average trading volume of 4860 shares – with shares dropping to a 52 week low of $5.90, and the company’s shares hitting a 52 week high of $ 25.17.
Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for NewLink Genetics Corporation the EPS stands at -0.57 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.73, suggesting the stock exceeded the analysts’ expectations.
Another critical number in evaluating a stock is P/E or the price to earnings ratio.
The TTM operating margin is 0%. The return on invested capital at -65.7%, which is good, compared to its peers.
The Free Cash Flow or FCF margin is 0%, which means that the business has healthy reserve funds for contingencies that may arise.
Stock is currently moving with a positive distance from the 200 day simple moving average of approximately 8.59%, and has a solid year to date (YTD) performance of 32.3% which means the stock is constantly adding to its value from the previous fiscal year end price.
The target price for NewLink Genetics Corporation (NLNK) is $14.8/share according to the consensus of analysts working on the stock, with an expected EPS of $-0.77/share for the current quarter.